


are no longer valid. CPT® codes, descriptions and other data are copyright 2018 American Medical Association (or such other date of publication of CPT®), All Rights Reserved, CPT® is a registered trademark of the American Medical Association. Code descriptions and billing scenarios are references from the AMA, CMS local and national coverage determinations (LCD/NCD),and standards nationwide.

COD

2


Revenue


















- · Introduced in PAMA
- Utilization of Appropriate Use Criteria (AUC) for advanced diagnostic studies

CODIN

- CT
- MR

REVENUE

- Nuclear Medicine - including PET

7


CMS c	an only approve the AUC that are	
develo (PLEs)	ped or endorsed by provider-led e	entities
	pe evidence based j is on CMS's website	
develo conside	a PLE is "qualified" all of the AUC ped or endorsed by that PLE are ered to be "specified AUC" for the ses of the requirements.	


8

Clinical Decision Support

8 priority clinical areas

- Coronary artery disease (suspected or diagnosed)
- Suspected pulmonary embolism
- Headache (traumatic and non-traumatic)
- Hip pain
- Low back pain
- Shoulder pain (to include suspected rotator cuff)
- Cancer of the lung (primary or metastatic, suspected or diagnosed)
- Cervical or neck pain





11





- · Requirement is that AUC must be consulted
- · Radiologists will not be exempt
- Does not apply to inpatient, certain emergency studies or to ordering physicians who qualify for a hardship exception
- There are no hardships for furnishing professionals
- CAHs are exempt
- Ordering professionals must communicate the results of the consultation to the imaging provider
 Facility & Radiologist


right® 2017 CSI All Rights Re

CODINGSTR


REVENUE










	ementation	
2020 w	ill be a testing year	
	re will pay regardless of whether or no	t
Beginn denied	ing January 1, 2021 payment will be if the furnishing professionals' claims e required ALIC information	
		16






















23

Next Steps

- Specifically clarify your organization's issues and concerns
- Have a clear plan to address
- Learn from others good, bad & ugly
- Watch for more CMS updates and incorporate into your plans


COL

Revenue CYCLE

purces / Practice with CareSelect	
ee with CareColect	
er Data button to begin practicing with the trial clinical decision support tool. When finished, click My Report to view a report	t example. After the case is successfully
Access the imaging clinical decision support web portal	
Enter case data	
Instructions	
the	tice with CareSelect the solution they experiment where do not access aspect to the hold did by bench one a new the new house an experimentary. Access the imaging clinical decision support web portal Enter case data and immunors



				J11	
	ect Body Area				
ACRselect					Logged in an
Create Session					
get 65 + Male Female	Unknown Q, swelling			Switch to Modality Mode	@ feedbal
Body Areas	Cincel Industors Industry	Clinical Scenarios			Secure
Abdomen.		. none			
Abdorren Breast	Sigvitympton	Suspected Lower Extremit	y Deep Vein Thrombosis		
Cardia	Anke erythema, swelling, celuitis suspected Knee erythema, swelling, celuitis suspected	C Leg swelling or pain, D			
Chest	Lower kep erythema, swelling, celluits suspected		f the Foot in Patients with Dial	petes Melitus	
Head	 Upper leg erythema, swelling, celluitis suspected 		d. Root swelling, no arthropathy, o		
Lover extremity			d. Not swelling, no arthropathy, y		
Maxface		Oteonyetts suspecte Oteonyetts suspecte	 toot swelling, yes arthropathy, toot swelling, yes arthropathy. 	no ucer, dabetic pt ves uker, dabetic pt	
Neck					
Petvis					
Appropriateness rankings	for a 63 year old female			Displa	ay Evidence
indications: Knee erg	therea, swelling, cellulois surported				
Appropriateness	Procedure	Cost	RRL		
	9 US, duplex doppler, lower extremity	\$\$\$		select this exam	
-	9 US, duplex doppler, lower extremity, venous	\$\$\$		select this exam	
	7 CT, venography, pelvis-lower extremity, w iv contrast	\$\$\$\$	***	select this exam	
	MR, venography, pelvis-lower extremity, wo iv contrast	5555		select this exam	
	MR, venography, pelvis-lower extremity, wolw iv contrast	\$\$\$\$		select this exam	
	6 INV, venography, pelvis		**	select this exam	
	4 INV, venography, lower extremity		**	select this exam	






CRselect						Logged in an (
reate Session							
30 * Mate Fenale U	Room Q. Filerindications/comarios				Switch to Indication Mode	Of Feedback	
dalities	Eody Areas	Clinical Indications	behabas	Clinical Scenarios		bears.	
	abdorren	Neoplasm breast slaging		 Intellity, patitionheal on exam 			
0	ana dideed	Necolaam chest hemeilumphatic staping		Non-Invasive Clinical Staging of Bronchogenic Carolinoma			
END.	accorrect	 Heopteen chest, tung, staging Heopteen chest, metadotic, staging 		C Long cancer, non-small cell, slaging			
FLUOR.	rheat	Neoplasm chest, other primary, staping		Long cancer, small sell, staging			
87	head	Neoptram extremity cutareous, attaging		Orbits, Vision and Visual Loss			
Mild	Intel	Heoplasm head, ChS, staging Heoplasm head, herefurnstatis, staging		CpRthatnoplegia Vessid loss after head interv			
MED	lowsr extremity	Neoplasm head, metastatic, staging		Veud loss, painful and/or prophosis			
MR	madate	Bioglaam Haadhadk, Kapig Bioglaam madhata, banogeng Bioglaam madhat, banogeng Bioglaam madhat, bioglaag Bioglaam manasholining, sitigang Bioglaam spandining, sitigang Bioglaam thysol, sitigang		Veuil kest, subles small			
NUC	hedt			 Vaual loss, uveilla, scientia 			
PEM	pelvis			Renal Cell Carcinoma Staging			
1967	again a			Renal cell cancer, slaging Post-line alment Policie-up of Renal Cell (
PET-CT	upper extremity			Recalced cancer, beated, assertions			
45	whole body						
US-XBAY XBay							
repreteness rankings for a 30 y	sar old female				Dep	iay Evidence	
	A long straping 1 Headache, new, minute compromise	or cancer 11					
ropriateness	Procedure		Cost	ML.			
	MR, head, work in contrast		8558		select this eram		
	MR, head, wo in contrast		555		seled this eram		
	CT, head, wiv contrast		55	999	seled this erain		
	CT, head, wolw in contrast		55		which this errors		
	CT, angingraphy, head, wilv contr		5555		salari Bia aram		
	C I head, we in contrast		11		select this even		
	5 MR, angiography, head, wo iv core		\$55		select this exam		


Г














31

	Care Se	HECL L	-лап	ihie	(3)
	ppropriateness Criteria			-	
	ppropriateriess Criteria	AC List			
and Type. Releat ALL	Panels: Ma	scular M		The C	Jear]
		Diagnostic			
		Vascular			
Topic I	Nome	Namative & Rating Table	Evidence Table	Lit Search	Appendix
Indominal Acetic Amerrysm Follow-up (Without Repair)		Namative & Rating Table	📆 Evidence Table	📆 Lit Search	📆 Appendix
bdominal Aortic Aneurysm: Interventional Planning and F	'oliow-ap	Narrative & Rating Table	👫 Evidence Table	📆 Lit Bearch	📆 Appendix
lant Abdominal Trauma		Nersalive & Rading	📆 Evidence Table		📆 Appendix
Runt Chest Trauma — Suspected Aortic Injury		Nerrative & Rating	Evidence Table	📆 Lit Gearch	📆 Appendix
Tryfothonax Treatment Planning		Namative & Rating	📆 Evidence Table	📆 Lit Search	📆 Appendix
linically Suspected Polynomery Arteriovenous Malformatic	on (PANM)	Narrative & Rating	📆 Evidence Table	📆 Lit Search	📆 Appendix
linically Suspected Vascular Malformation of the Extremit	ies	Narrative & Rating Table	💏 Evidence Table	💏 Lit Search	🖷 Appendix
naging for Transcatheter Acrtic Valve Replacement		Namative & Rating	📆 Evidence Table	📆 Lit Gearch	📆 Appendix
naging in the Diagnosis of Thoracic Outlet Syndrome		Namative & Rating	Cvidence Table		📆 Appendix
maging of Deep Inferior Epigastric Arteries for Surgical Pla	anning (Broast Reconstruction Surgery)	Narrative & Rating	📆 Evidence Table	📆 Lit Search	📆 Appendix
naging of Mesenteric Ischemia		Table	📆 Evidence Table	📆 Lit Search	📆 Appendix
ower Extremity Arterial Revescularization-Post-Therapy In	meging	Namative & Ralling Table	👯 Evidence Table	📆 Lit Search	📆 Appendix
ionatheroscierotic Peripheral Arterial Disease		Namative & Rating	Cvidence Table	H Gearch	R Appendix








ACCC Reimbursement Meeting 2019 Oncology Coding Updates Augusta Georgia





34


































44






Medically Appropriate History/PE


(A) Removing history and examination as key components for selecting the level of E/M service, but adding the requirement that a medically appropriate history and/or examination must be performed in order to report codes 99202-99215;

Read full summary for additional details on changes to E/M codes 99202-99215


CODING


46






















CAR T-cell Therapy Codes (CAR) T-cell therapy is cell-based gene therapy, T-cells are collected and genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient's cancerous cells. CAR T-cells are administered to the patient to attack certain cancerous cells and observed for potential serious side effects that would

(CO)

require medical intervention.

53

REVENUE



Modifiers 59 and X Update

Modification of the MCS Claims Processing System Logic for Modifier 59, XE, XS, XP, and XU Involving the National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) Column One and Column Two Codes, Effective July 1, 2019

https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/MM11168.pdf

CODI

REVENUE

55

MM11168

PROVIDER TYPE AFFECTED

This MLN Matters® Article is for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

PROVIDER ACTION NEEDED

CR11168 informs MACs about changes to National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) edits which consist of column one and column two codes. Make sure that your billing staffs are aware of these changes

BACKGROUND


REVENUE

Modifiers 59, XE, XS, XP, and XU are among the NCCI-associated modifiers. The Multi-Carrier System (MCS) currently requires that modifiers 59, XE, XS, XP, or XU be appended to the column two code of a PTP edit to bypass the edit. With the implementation of CR 11168, Medicare will allow modifiers 59, XE, XS, XP, or XU on column one and column two codes to bypass the edit.

56

	new H	CPCS codes will be payable for Medicare,
	for clai	ms with dates of service on or after July 1,
2019	CODE	DESCRIPTION
	J1444	Fe pyro cit pow 0.1 mg iron
	J7208	Inj. jivi 1 iu
	J7677	Revefenacin inh non-com 1mcg
	J9030	Bcg live intravesical 1mg
	J9036	Inj., belrapzo/bendamustine
	J9356	Inj. herceptin hylecta, 10mg
	Q5112	Inj ontruzant 10 mg
	Q5113	Inj herzuma 10 mg
	Q5114	Inj ogivri 10 mg
C Doour	Q5115	Inj rituximab-abbs bio 10 mg
CACIÉ.	Copyright ^{er} 2019 CSI A	IR Rights Reserved/Copyright® 2018 RCI All Rights Reserved CPT only ® 2018 American Medical Association All Rights Reserved CODINGSTRATE






CODI

REVENUE

58



59



